
GRI Stock Forecast & Price Target
GRI Analyst Ratings
Bulls say
GRI Bio is a clinical-stage biotech company with a strong pipeline of potential treatments targeting serious diseases associated with dysregulated immune responses, including inflammatory, fibrotic, and autoimmune disorders. The company's lead drug candidate, GRI-0621, has shown promising results in Phase 2a trials, with positive biomarker data and a clean safety profile. This drug has the potential to differentiate itself in the market by not only slowing down but even reversing the underlying causes of IPF. With additional programs in development, potential partnerships, and a large addressable market, the company has significant upside potential. However, investors should consider risks such as potential funding issues, clinical trial failures, and commercialization challenges. Based on a clinical net present value (NPV) model, a valuation of $10 per share may underestimate the long-term potential for GRI Bio.
Bears say
GRI Bio is a clinical-stage biopharmaceutical company focused on developing treatments for immune-related diseases through their novel small molecule therapies GRI-0621 and GRI-0803. While the company has displayed positive topline data and raised a decent amount of capital, their recent financial performance and on-going clinical studies place them in a precarious position, leading to the negative outlook from this financial analyst.
This aggregate rating is based on analysts' research of GRI Bio Inc and is not a guaranteed prediction by Public.com or investment advice.
GRI Analyst Forecast & Price Prediction
Start investing in GRI
Order type
Buy in
Order amount
Est. shares
0 shares